Blog Standard

Nov

The Biosimilar Wars: Competing Beyond Price in 2025

The biosimilar market was supposed to be simple: copy the molecule, undercut the price, capture the share. Instead, it’s become one of the most complex battlefields in pharma. At Octavus Consulting, we’ve spent the last two years helping clients navigate this chaos. Price erosion is inevitable, but profit erosion is optional. The winners are those […]

Oct

Competitive Intelligence No Comments

Learning from Trial Failures: Turning Setbacks into Strategic Data Assets

Every company has a “Phase III heartbreak.” The molecule looked perfect—mechanism sound, safety profile strong—but the primary endpoint missed. Most teams bury the data. At Octavus Consulting, we treat it as a gold mine. The Opportunity in Failure Clinical failures hold information about trial design, recruitment, and patient heterogeneity that can redefine the next success. […]

Oct

Business Research No Comments

Strategic Intelligence in Biopharma M&A: Seeing the Deal Before It Happens

When Gilead acquired Forty Seven Inc. in 2020, most observers called it quick. Those who tracked macrophage checkpoint research knew it was inevitable. That’s the power of strategic intelligence—not reacting to news, but foreseeing inevitabilities. At Octavus Consulting, we help clients move from rumor-driven scouting to pattern-based acquisition strategy. In 2025’s market—where capital discipline and […]

Oct

Business Research, Data Analytics No Comments

Real-World Evidence 2.0: From Post-Market Validation to Strategic Design

In 2025, Real-World Evidence (RWE) is no longer an afterthought in regulatory filings. It’s a design principle. We recently worked with a biotech firm developing an oncology therapy struggling with limited trial enrollment and payer skepticism. Instead of waiting until post-launch to demonstrate real-world value, they embedded RWE from day one. By integrating claims and […]

Oct

Business Consulting No Comments

The 2025 CDMO Landscape: Partnership Beyond Procurement

When a biotech misses its launch date, it’s rarely the science that fails — it’s the supply chain. In one 2024 case, a company developing a monoclonal antibody chose a CDMO solely based on cost per gram. Six months later, batch failures forced a rework that doubled expenses and delayed market entry by nearly a […]

Oct

Competitive Intelligence No Comments

From Data to Decisions: How AI Is Redefining Competitive Intelligence in Pharma

At Octavus Consulting, we often see pharma teams with all the right data but none of the right speed. They have dashboards, trackers, and CI reports — yet, when a competitor announces trial success or a new filing, the organization reacts days or even weeks later. The gap isn’t data. It’s decision latency. In one […]

Octavus Consulting- Evidence-Based Consulting Services.

The Biosimilar Wars: Competing Beyond Price in 2025

Learning from Trial Failures: Turning Setbacks into Strategic Data Assets

Strategic Intelligence in Biopharma M&A: Seeing the Deal Before It Happens

Real-World Evidence 2.0: From Post-Market Validation to Strategic Design

The 2025 CDMO Landscape: Partnership Beyond Procurement

From Data to Decisions: How AI Is Redefining Competitive Intelligence in Pharma

Categories

Subscribe Newsletter

Company Information

Our Services

Quick Links